Literature DB >> 12588916

S100B as a surrogate marker for successful clot lysis in hyperacute middle cerebral artery occlusion.

C Foerch1, R du Mesnil de Rochemont, O Singer, T Neumann-Haefelin, M Buchkremer, F E Zanella, H Steinmetz, M Sitzer.   

Abstract

OBJECTIVES: The astroglial protein S100B is a marker of cerebral tissue damage. This study investigated whether the serum kinetic of S100B may serve as a surrogate marker of successful clot lysis and early recanalisation (<6 hours) in hyperacute proximal middle cerebral artery (MCA/M1) occlusion.
METHODS: The authors prospectively included 23 patients (mean (SD) age, 70.2 (11.0) years) presenting with MCA/M1 occlusion on magnetic resonance angiography (n=18), intra-arterial angiography (IA; n=2), or transcranial Doppler sonography (TCD; n=3) within five hours after symptom onset. Rates of recanalisation and their point of time were determined using TCD or IA. Individual S100B values were determined at hospital admission, every eight hours within the first three days, and at 12 hour intervals from day 4 to day 6. Additionally, the S100B area under the curve (AUC) and the S100B peak value were obtained.
RESULTS: Early recanalisation (<6 hours after symptom onset, n=7) was associated with a significantly lower mean S100B AUC compared with no recanalisation (22.2 (40.1) versus 406.8 (284.4) micro g/l per hour; p<0.001). Using receiver operating calculations, a single S100B value obtained 48-96 hours after stroke onset of less than 0.4 micro g/l (cut off point) provided a 86% sensitivity and 100% specificity for sufficient MCA/M1 clot lysis <6 hours. The overall accuracy for a single S100B value obtained in the 48-96 hours time window was as high as for the AUC (95.7%).
CONCLUSION: A single S100B value <0.4 micro g/l obtained 48-96 hours after stroke onset indicates successful clot lysis <6 hours in MCA/M1 occlusion with a high degree of accuracy. Thus, determination of a single S100B value may serve as a surrogate marker of early and sufficient MCA/M1 recanalisation in large scale thrombolytic studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12588916      PMCID: PMC1738319          DOI: 10.1136/jnnp.74.3.322

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  24 in total

Review 1.  Thrombolysis in acute cerebrovascular disease: indications and limitations.

Authors:  W Hacke; P Ringleb; R Stingele
Journal:  Thromb Haemost       Date:  1999-08       Impact factor: 5.249

2.  Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI.

Authors:  P D Schellinger; O Jansen; J B Fiebach; S Heiland; T Steiner; S Schwab; O Pohlers; H Ryssel; K Sartor; W Hacke
Journal:  Stroke       Date:  2000-06       Impact factor: 7.914

3.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.

Authors:  W M Clark; S Wissman; G W Albers; J H Jhamandas; K P Madden; S Hamilton
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

4.  Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia.

Authors:  P D Schellinger; J B Fiebach; O Jansen; P A Ringleb; A Mohr; T Steiner; S Heiland; S Schwab; O Pohlers; H Ryssel; B Orakcioglu; K Sartor; W Hacke
Journal:  Ann Neurol       Date:  2001-04       Impact factor: 10.422

5.  Hyperdense sylvian fissure MCA "dot" sign: A CT marker of acute ischemia.

Authors:  P A Barber; A M Demchuk; M E Hudon; J H Pexman; M D Hill; A M Buchan
Journal:  Stroke       Date:  2001-01       Impact factor: 7.914

6.  Thrombolysis in brain ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator.

Authors:  A M Demchuk; W S Burgin; I Christou; R A Felberg; P A Barber; M D Hill; A V Alexandrov
Journal:  Stroke       Date:  2001-01       Impact factor: 7.914

7.  Transcranial doppler ultrasound criteria for recanalization after thrombolysis for middle cerebral artery stroke.

Authors:  W S Burgin; M Malkoff; R A Felberg; A M Demchuk; I Christou; J C Grotta; A V Alexandrov
Journal:  Stroke       Date:  2000-05       Impact factor: 7.914

8.  Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein.

Authors:  M Herrmann; P Vos; M T Wunderlich; C H de Bruijn; K J Lamers
Journal:  Stroke       Date:  2000-11       Impact factor: 7.914

9.  Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke.

Authors:  C A Molina; J Montaner; S Abilleira; B Ibarra; F Romero; J F Arenillas; J Alvarez-Sabín
Journal:  Stroke       Date:  2001-05       Impact factor: 7.914

10.  Bootstrap statistics of ECASS II data: just another post hoc analysis of a negative stroke trial?

Authors:  R Stingele; E Bluhmki; W Hacke
Journal:  Cerebrovasc Dis       Date:  2001       Impact factor: 2.762

View more
  15 in total

1.  Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke.

Authors:  Michael T Wunderlich; Thorsten Hanhoff; Michael Goertler; Friedrich Spener; Jane F C Glatz; Claus-W Wallesch; Maurice M A L Pelsers
Journal:  J Neurol       Date:  2005-04-18       Impact factor: 4.849

2.  Does serum Tau protein predict the outcome of patients with ischemic stroke?

Authors:  Joanna Bielewicz; Jacek Kurzepa; Elżbieta Czekajska-Chehab; Zbigniew Stelmasiak; Halina Bartosik-Psujek
Journal:  J Mol Neurosci       Date:  2010-06-12       Impact factor: 3.444

Review 3.  Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Debra Lynch Kelly; David Buchbinder; Rafael F Duarte; Jeffrey J Auletta; Neel Bhatt; Michael Byrne; Zachariah DeFilipp; Melissa Gabriel; Anuj Mahindra; Maxim Norkin; Helene Schoemans; Ami J Shah; Ibrahim Ahmed; Yoshiko Atsuta; Grzegorz W Basak; Sara Beattie; Sita Bhella; Christopher Bredeson; Nancy Bunin; Jignesh Dalal; Andrew Daly; James Gajewski; Robert Peter Gale; John Galvin; Mehdi Hamadani; Robert J Hayashi; Kehinde Adekola; Jason Law; Catherine J Lee; Jane Liesveld; Adriana K Malone; Arnon Nagler; Seema Naik; Taiga Nishihori; Susan K Parsons; Angela Scherwath; Hannah-Lise Schofield; Robert Soiffer; Jeff Szer; Ida Twist; Anne Warwick; Baldeep M Wirk; Jean Yi; Minoo Battiwalla; Mary E Flowers; Bipin Savani; Bronwen E Shaw
Journal:  Biol Blood Marrow Transplant       Date:  2017-09-20       Impact factor: 5.742

4.  Serum S100β as a predictor of severity and outcomes for mixed subtype acute ischaemic stroke.

Authors:  Siwat Sakdejayont; Nannapat Pruphetkaew; Pensri Chongphattararot; Paveena Nanphan; Pornchai Sathirapanya
Journal:  Singapore Med J       Date:  2019-07-11       Impact factor: 1.858

5.  The use of serum glial fibrillary acidic protein test as a promising tool for intracerebral hemorrhage diagnosis in Chinese patients and prediction of the short-term functional outcomes.

Authors:  Lijun Xiong; Yan Yang; Mei Zhang; Wuping Xu
Journal:  Neurol Sci       Date:  2015-07-21       Impact factor: 3.307

6.  Astroglial proteins as diagnostic markers of acute intracerebral hemorrhage-pathophysiological background and clinical findings.

Authors:  Robert Brunkhorst; Waltraud Pfeilschifter; Christian Foerch
Journal:  Transl Stroke Res       Date:  2010-08-28       Impact factor: 6.829

Review 7.  S100 as a marker of acute brain ischemia: a systematic review.

Authors:  David L Nash; M Fernanda Bellolio; Latha G Stead
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

Review 8.  Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT.

Authors:  David Buchbinder; Debra Lynch Kelly; Rafael F Duarte; Jeffery J Auletta; Neel Bhatt; Michael Byrne; Zachariah DeFilipp; Melissa Gabriel; Anuj Mahindra; Maxim Norkin; Helene Schoemans; Ami J Shah; Ibrahim Ahmed; Yoshiko Atsuta; Grzegorz W Basak; Sara Beattie; Sita Bhella; Christopher Bredeson; Nancy Bunin; Jignesh Dalal; Andrew Daly; James Gajewski; Robert Peter Gale; John Galvin; Mehdi Hamadani; Robert J Hayashi; Kehinde Adekola; Jason Law; Catherine J Lee; Jane Liesveld; Adriana K Malone; Arnon Nagler; Seema Naik; Taiga Nishihori; Susan K Parsons; Angela Scherwath; Hannah-Lise Schofield; Robert Soiffer; Jeff Szer; Ida Twist; Anne B Warwick; Baldeep M Wirk; Jean Yi; Minoo Battiwalla; Mary D E Flowers; Bipin Savani; Bronwen E Shaw
Journal:  Bone Marrow Transplant       Date:  2018-01-17       Impact factor: 5.483

9.  Decreased Serum Levels of S-100B Protein Reflect Successful Treatment Effects in a Rabbit Model of Acute Ischemic Stroke.

Authors:  Sean D Woods; Rene Flores; Paula K Roberson; John D Lowery; Robert D Skinner; William C Culp
Journal:  Open Neurol J       Date:  2011-06-21

Review 10.  Monitoring biomarkers of cellular injury and death in acute brain injury.

Authors:  Sherry H-Y Chou; Claudia S Robertson
Journal:  Neurocrit Care       Date:  2014-12       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.